One-time gene therapy switched off a cholesterol driver for 3 years in monkeys
☕ Includes a question for the family ↓
Gene and cell therapiesPart of a story we are following · 4 articles · See every update
If you have ever wished you could fix your cholesterol once and be done with it, this one is for you. Scientists have built a one-time gene therapy that switches off a cholesterol-raising gene in the liver, and in monkeys the effect lasted 3 years. A first trial in people is now under way.
In lab and animal tests reported in Nature, a single infusion of this gene therapy cut levels of a liver protein called ANGPTL3 by more than 90% in monkeys, and it lowered LDL (“bad”) cholesterol and triglycerides in both mice and monkeys. The work was done in human liver cells, mice and monkeys. It is not approved by the FDA yet, and it is not something you can get today.
How the study worked
The team tested the treatment in human liver cells in the lab, then in mice and in monkeys, and reported the results in Nature on November 6, 2026. This was early-stage research in cells and animals, so the numbers describe what happened there, and the human trial now under way will show how people respond.
What is ANGPTL3, and what is base editing?
ANGPTL3 is a protein made in your liver. It is known to push up both LDL cholesterol and triglycerides, which are the two blood fats most tied to heart and artery disease.
Base editing is a very precise kind of gene tool. Think of your DNA as a very long book. A base editor goes to one spot and changes a single letter, which turns that gene off. Here, the editing tools are packed into a tiny fat bubble that is built to head for the liver. The treatment is given as one infusion, not a pill you take every day.
What did they find?
The results were strong on several fronts:
- The target protein dropped sharply. In monkeys, the treatment brought a mean reduction of more than 90% (reported as “> 90%”) in circulating ANGPTL3 protein. It was well tolerated.
- The effect lasted. After a single dose, the drop was still confirmed 3 years later.
- Cholesterol and triglycerides went down. In mouse and monkey models of high blood fats, LDL cholesterol fell by approximately 40 to 50%, and triglycerides fell by approximately 50 to 70%.
- The edit landed where it was aimed. In human liver cells, the editor made the intended one-letter change. The team found no off-target editing at any of approximately 3,000 candidate sites they checked, and no treatment-related structural changes to the DNA.
The researchers point to a gap in care today. Even with several approved cholesterol medicines, most patients do not reach their target levels when they have to keep up long-term treatment. A single-course option aims right at that gap.
These results gave the team the scientific foundation to start a first-in-human clinical trial. It is enrolling patients with hard-to-treat high blood fat conditions.
What you can do today
This therapy is still being tested, so the best move now is to know your own starting point. Open your patient portal or find your last lab report, look for your LDL cholesterol and triglycerides, and write both numbers on a sticky note. Put it somewhere you will see it, like the fridge or your calendar. Then you will be ready to follow this story as it moves forward.
Talk about it at home
Inside your liver, a gene works like a line in a giant recipe book, telling the body to make a protein that pushes up the fats in your blood. Scientists built a tiny tool that finds that exact line and changes a letter, like fixing a typo with a very careful eraser, so the recipe stops being followed. They tried it in monkeys and kept watching for a long time, and the change was still working.
Try it at home
Look up together why scientists study mice and monkeys long before a new idea is tried in people, and see if you can find another animal that has helped science learn something surprising.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. One-time gene therapy switched off a cholesterol driver for 3 years in monkeys. Mongevity. Published November 9, 2026. Accessed November 22, 2026. https://mongevity.science/mongevity-tech/2026/11/one-time-gene-therapy-cholesterol-monkeys/Mongevity Desk. One-time gene therapy switched off a cholesterol driver for 3 years in monkeys [Internet]. Mongevity; 2026 Nov 9 cited 2026 Nov 22]. Available from: https://mongevity.science/mongevity-tech/2026/11/one-time-gene-therapy-cholesterol-monkeys/Mongevity Desk. (2026, November 9). One-time gene therapy switched off a cholesterol driver for 3 years in monkeys. Mongevity. https://mongevity.science/mongevity-tech/2026/11/one-time-gene-therapy-cholesterol-monkeys/
<a href="https://mongevity.science/mongevity-tech/2026/11/one-time-gene-therapy-cholesterol-monkeys/">One-time gene therapy switched off a cholesterol driver for 3 years in monkeys</a>
Free to share or quote with credit and a link.
Questions and answers
- Can I get this cholesterol gene therapy now?
- No. It is not approved by the FDA yet. So far it has been tested in human liver cells, mice and monkeys, and a first trial in people with hard-to-treat high blood fats is under way.
- What does the gene therapy do?
- It turns off a liver gene called ANGPTL3 with a single infusion. That protein is known to raise LDL cholesterol and triglycerides, so switching it off brought both down in animal tests.
- How long did the effect last?
- In monkeys, the large drop in ANGPTL3 protein was confirmed 3 years after one dose.
- How much did cholesterol and triglycerides fall?
- In mouse and monkey models, LDL cholesterol fell by approximately 40 to 50%, and triglycerides fell by approximately 50 to 70%.


